Patents by Inventor Andrés OZAITA

Andrés OZAITA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
    Publication number: 20220017562
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a cognitive disorders. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of cognitive disorders. Indeed, the compound of the invention is in vivo very potent in correcting the cognitive impairments observed in cognitive disorders.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 20, 2022
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Stéphanie MONLEZUN, Mathilde METNA, Monique VALLEE, Jean-Michel REVEST, Daniela COTA, Giovanni MARSICANO, Aline MARIGHETTO, Andrés OZAITA, Rafael MALDONADO
  • Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
    Patent number: 9662320
    Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: May 30, 2017
    Assignee: Universitat Pompeu Fabra
    Inventors: Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez
  • Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities
    Publication number: 20160067235
    Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
    Type: Application
    Filed: March 19, 2013
    Publication date: March 10, 2016
    Inventors: Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez